Literature DB >> 15468380

Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.

Pascal Richette1, Philippe Dieudé, Joël Damiano, Frédéric Lioté, Philippe Orcel, Thomas Bardin.   

Abstract

We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15468380

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  17 in total

1.  Isolated motor conduction block associated with infliximab.

Authors:  A W Michell; A Gaitatzis; J Burge; M M Reilly; R Kapoor; M Koltzenburg
Journal:  J Neurol       Date:  2012-02-18       Impact factor: 4.849

2.  Bilateral diaphragmatic paralysis associated with the use of the tumor necrosis factor-alpha inhibitor adalimumab.

Authors:  Mina Mecheal Benjamin; Alan William Martin; Randall Lee Rosenblatt
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-04

3.  Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment.

Authors:  Maria G Tektonidou; John Serelis; Fotini N Skopouli
Journal:  Clin Rheumatol       Date:  2006-07-06       Impact factor: 2.980

4.  Tumour necrosis factor alpha blockade and the risk of vasculitis.

Authors:  M De Bandt; B Saint-Marcoux
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

5.  Infliximab-associated neuropathy in RA patients--the importance of considering the diagnosis of mononeuritis multiplex.

Authors:  J Birnbaum
Journal:  Clin Rheumatol       Date:  2006-10-25       Impact factor: 2.980

6.  Investigation of effects of two-different treatment modalities on nerve conduction in patients with ankylosing spondylitis.

Authors:  Erhan Capkin; Murat Karkucak; Muammer Muslim Kose; Vildan Altunayoğlu Çakmak; Aysegul Kucukali Turkyilmaz; Mehmet Tosun
Journal:  Rheumatol Int       Date:  2010-12-01       Impact factor: 2.631

Review 7.  Monoclonal antibody therapy-associated neurological disorders.

Authors:  Xavier Bosch; Albert Saiz; Manuel Ramos-Casals
Journal:  Nat Rev Neurol       Date:  2011-01-25       Impact factor: 42.937

Review 8.  Neurological adverse events associated with anti-tumor necrosis factor α treatment.

Authors:  Antonio G Tristano
Journal:  J Neurol       Date:  2010-05-22       Impact factor: 4.849

9.  Non-length-dependent and length-dependent small-fiber neuropathies associated with tumor necrosis factor (TNF)-inhibitor therapy in patients with rheumatoid arthritis: expanding the spectrum of neurological disease associated with TNF-inhibitors.

Authors:  Julius Birnbaum; Clifton O Bingham
Journal:  Semin Arthritis Rheum       Date:  2013-10-30       Impact factor: 5.532

Review 10.  Biologic treatments for systemic rheumatic diseases.

Authors:  Y Shirota; G G Illei; N P Nikolov
Journal:  Oral Dis       Date:  2008-02-14       Impact factor: 3.511
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.